GSK CEO's performance pay slides

GlaxoSmithKline ($GSK) CEO Andrew Witty has another reason to lament European austerity. Witty's performance-based pay totaled £2.81 million for 2012, down from £5.74 million in 2011. (That's about $4.24 million and $8.6 million, respectively, at today's exchange rates.) His total compensation came in at £3.89 million. In dollars, Witty's 2012 compensation amounted to about $5.86 million. R&D chief Moncef Slaoui lost proportionately less. In fact, thanks to the research group's "very successful year," his total compensation came in at $3.09 million, down from $3.5 million in 2011, as he qualified for 67% of his possible performance-pay max. Total compensation for the year: $4.61 million. Story

Editor's note: This story has been corrected; The original item inaccurately cited Moncef Slaoui's pay in GBP, which were converted to a higher dollar rate. Slaoui actually earned somewhat less than Witty last year.

 

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.